BioAtla, Inc.
BCAB
$4.54
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | 0.00 | 11.00M | 11.00M | 11.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | 0.00 | 11.00M | 11.00M | 11.00M |
| Cost of Revenue | 43.57M | 47.23M | 54.08M | 56.60M | 63.10M |
| Gross Profit | -41.57M | -47.23M | -43.08M | -45.60M | -52.10M |
| SG&A Expenses | 17.73M | 19.07M | 20.69M | 21.50M | 21.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.31M | 66.29M | 74.78M | 78.10M | 84.94M |
| Operating Income | -59.31M | -66.29M | -63.78M | -67.10M | -73.94M |
| Income Before Tax | -59.61M | -64.71M | -59.52M | -61.88M | -69.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.61 | -64.71 | -59.52 | -61.88 | -69.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.61M | -64.71M | -59.52M | -61.88M | -69.78M |
| EBIT | -59.31M | -66.29M | -63.78M | -67.10M | -73.94M |
| EBITDA | -58.93M | -65.71M | -63.02M | -66.23M | -73.02M |
| EPS Basic | -50.76 | -57.57 | -55.09 | -60.95 | -71.95 |
| Normalized Basic EPS | -31.73 | -35.98 | -34.43 | -38.10 | -44.97 |
| EPS Diluted | -50.76 | -57.57 | -55.09 | -60.95 | -71.95 |
| Normalized Diluted EPS | -31.73 | -35.98 | -34.43 | -38.10 | -44.97 |
| Average Basic Shares Outstanding | 4.71M | 4.50M | 4.29M | 4.09M | 3.89M |
| Average Diluted Shares Outstanding | 4.71M | 4.50M | 4.29M | 4.09M | 3.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |